JUBLPHARMAJubilant Pharmova Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

₹1,023.85

▲ 0.12%

Decent

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)15,434.00

P/E38.82

P/B2.17

PEG0.14

ROE %5.96

ROCE %7.70

Debt / Equity0.51

EPS25.10

Revenue Growth %18.70

Profit Growth %-22.40

Dividend Yield %0.49

Promoter Holding %57.95

FII Holding %21.61

DII Holding %—

Beta0.51

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on JUBLPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 70%

The picture

• Revenue growth: 18.7% YoY
• Debt/Equity: 0.51
• Promoter holding: 58.0%
• RSI: 66
• MACD: bullish
• Price vs EMA21: above

Bull case

• Revenue growth: 18.7% YoY
• Debt/Equity: 0.51
• Promoter holding: 58.0%
• RSI: 66

Bear case

• Profit growth: -22.4% YoY
• ROE: 6.0%
• Golden cross setup: SMA50 below SMA200
• Volume: 0.6x 20-day average

Key risks

• Profit growth: -22.4% YoY
• ROE: 6.0%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)

₹1,023.85

Stop Loss

₹957.96

risk 6.4%

Target 1 (1.5R)

₹1,122.69

+9.7%

Target 2 (3R)

₹1,221.53

+19.3%

Support (20d)

₹950.25

Resistance (52w)

₹1,248.00

Risk : Reward

1 : 1.5 → 1 : 3

risking ₹65.89/share

ATR (volatility)

₹26.36

avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹26.36). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental

Technical

Momentum

Risk (safety)

Peers — Pharma

About

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.